On December 19, 2023 Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, reported that it will be eligible to receive a milestone payment of $10 million from AstraZeneca (LSE/STO/Nasdaq: AZN), when the first patient is dosed in AstraZeneca’s ARTEMIDE-Bil01 trial with rilvegostomig (Press release, Compugen, DEC 19, 2023, View Source [SID1234638696]). Rilvegostomig is a PD-1/TIGIT bispecific antibody where the TIGIT component is derived from Compugen’s clinical-stage anti-TIGIT antibody, COM902. The ARTEMIDE-Bil01 trial is expected to recruit about 750 subjects in more than 20 countries with biliary tract cancer who will be randomized to receive rilvegostomig or placebo with investigator choice chemotherapy as adjuvant treatment after resection with curative intent.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"I am delighted to see the advancement of rilvegostomig into Phase 3 by AstraZeneca, a global leader in oncology," said Anat Cohen-Dayag, Ph.D., President, and Chief Executive Officer of Compugen. "I believe that the progress of the rilvegostomig clinical program in this Phase 3 trial along with the Phase 1 and 2 trials in additional indications, demonstrates the commitment to explore the potential of this bispecific antibody, where the TIGIT component is derived from our anti-TIGIT antibody COM902."

About the Compugen-AstraZeneca license agreement

In 2018, Compugen and AstraZeneca entered into an agreement by which Compugen provided an exclusive license to AstraZeneca to use Compugen’s monospecific antibodies that bind to TIGIT, including COM902, for the development of bispecific and multispecific antibody products, excluding such bispecific and multispecific antibodies that also bind to PVRIG, PVRL2 and/or TIGIT. AstraZeneca is responsible for all research, development, and commercial activities. AstraZeneca has the right to create multiple products under this license. In addition to the $10 million milestone payment described here which Compugen will be eligible to receive on dosing of the first patient in the Phase 3 ARTEMIDE-Bil01 trial, Compugen has received a $10 million upfront payment, and an additional $15.5 million in milestone payments to date, all out of up to an aggregate milestone amount of $200 million that the Company is eligible to receive in development, regulatory and commercial milestones for the first product, as well as tiered royalties on future product sales. If additional bi- or multi-specific products are developed based on Compugen’s monospecific antibodies that bind to TIGIT, additional milestones and royalties would be due to Compugen.

Further details about ARTEMIDE-Bil01 trial are available on ClinicalTrials.gov, identifier: NCT06109779.

On December 19, 2023 TC BioPharm (Holdings) plc ("TC BioPharm" or the "Company") (NASDAQ: TCBP), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, reported the pricing of a public offering of 1,750,000 of its American Depositary Shares (the "ADSs") (or pre-funded warrants in lieu thereof), together with Series E warrants (the "Series E Warrants") to purchase up to 1,750,000 of its ADSs at a public offering price of $2.00 per ADS (or pre-funded warrant in lieu thereof) and associated Series E Warrant (Press release, TC Biopharm, DEC 19, 2023, View Source [SID1234638695]). The Series E Warrants will have an exercise price of £1.5814 per ADS, are exercisable upon issuance and will expire five years following the date of issuance. Each ADS represents twenty ordinary shares of the Company. The closing of the offering is expected to occur on or about December 21, 2023, subject to the satisfaction of customary closing conditions.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.

The gross proceeds to the Company from the offering are expected to be $3.5 million, before deducting the placement agent’s fees and other offering expenses payable by the Company. The Company intends to use the net proceeds from this offering to support its upcoming clinical trial focusing on relapse/refractory Acute Myeloid Leukemia, and for continuing operating expenses and working capital.

A registration statement on Form F-1 (File No. 333-274244) relating to the securities described above has been filed with the Securities and Exchange Commission, or the SEC, and was declared effective by the SEC on December 18, 2023. The offering will be made only by means of a prospectus, which is part of the effective registration statement. A preliminary prospectus relating to the offering has been filed with the SEC. When available, electronic copies of the final prospectus may be obtained for free on the SEC’s website located at View Source and may also be obtained by contacting H.C. Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor, New York, NY 10022, by phone at (212) 856-5711 or e-mail at [email protected].

The Company also has agreed that a certain existing warrant to purchase up to an aggregate of 623,750 ADSs of the Company that was previously issued on September 5, 2023, at an exercise price of £7.00 per ADS and an expiration date of March 5, 2029, will be amended effective upon the closing of the offering so that the amended warrant will have a reduced exercise price of £1.5814 per ADS.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

On December 19, 2023 The National Comprehensive Cancer Network (NCCN) Oncology Research Program (ORP) reported grants awarded to support clinical studies that will evaluate the efficacy and safety of elranatamab in the treatment of multiple myeloma (Press release, NCCN, DEC 19, 2023, View Source [SID1234638694]). Funding will be provided through support from Pfizer Global Medical Grants.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Globally, there are approximately 176,000 new cases and 117,000 deaths annually attributed to multiple myeloma. Multiple myeloma patients typically cycle through many lines of treatment, as resistance develops to preceding regimens. Elranatamab is a BCMA-directed bispecific antibody that was recently granted accelerated approval by the FDA. The registrational study evaluated the efficacy and safety of elranatamab monotherapy in patients with relapsed, refractory multiple myeloma after prior treatment with at least one proteasome inhibitor, one immunomodulatory agent, and one anti-CD38 antibody.

"The aim of this initiative is to fund studies that will expand the growing body of evidence on the use of elranatamab to help advance treatment of patients with multiple myeloma," explained Crystal S. Denlinger, MD, Chief Executive Officer, NCCN. "Congratulations to these dedicated investigators. Their research will help further our understanding of how to optimize care for people with multiple myeloma."

The projects selected for approval are:

David Avigan, MD, Beth Israel Deaconess Medical Center
NCCN Pfizer Investigator-Sponsored Research Project to Evaluate the Effectiveness of a Personalized Cancer Vaccine in Conjunction with Elranatamab in the Treatment of Multiple Myeloma
Ah-Reum Jeong, MD, UC San Diego Moores Cancer Center
Phase II MRD Adapted Study of Elranatamab in Relapsed/Refractory Multiple Myeloma
Michael Slade, MD, Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine
Measurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance Using Peripheral Blood Clonotypic Mass Spectrometry
Attaya Suvannasankha, MD, Indiana University Melvin and Bren Simon Comprehensive Cancer Center and Richard L. Roudebush Veterans Administration Medical Center
Response-guided Treatment Discontinuation of Elranatamab in Frail/Elderly Patients
Proposals were peer reviewed by a Scientific Review Committee, which consisted of leading expert oncologists from NCCN Member Institutions. The selected projects are set to be completed within five years. Approximately $5 million in funding will be provided across all grants.

The NCCN ORP fosters innovation and knowledge discovery that improve the lives of people with cancer and supports preclinical, translational, and clinical research and quality improvement projects in oncology at NCCN Member Institutions. In an effort to improve collaboration in cancer research, the NCCN ORP also maintains a shared resources website, an informed consent database, and points to consider on the best practices for biorepositories, registries, and databases. For more information, visit NCCN.org/orp.

On December 19, 2023 Triumvira Immunologics, a clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with solid tumors, reported that it will present two abstracts at the 2024 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Gastrointestinal Cancers Symposium in San Francisco, California, from January 18-20, 2024 (Press release, Triumvira Immunologics, DEC 19, 2023, View Source [SID1234638693]). The company will showcase clinical data from its ongoing Phase I/II studies investigating the safety and efficacy of autologous TAC-T cells targeting human epidermal growth factor receptor 2 (HER2) and Claudin 18.2 (CLDN 18.2), respectively, in relapsed or refractory solid tumors (TACTIC-2 /NCT04727151, TACTIC-3 /NCT05862324).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The technology behind TAC01-HER2 and TAC01-CLDN18.2 stands as an innovative cell-based therapeutic modality, harnessing genetically engineered T cells derived autologously. These T cells are equipped with a T-cell Antigen Coupler (TAC) rationally designed to specifically recognize HER2 or CLDN18.2 within tumor cells.

"We are delighted to showcase the latest clinical developments of our Phase I/II study investigating the safety and efficacy of autologous TAC-T cells targeting HER2+ relapsed or refractory solid tumors and our first in human phase 1/2 trial targeting CLDN18.2-positive solid tumors," said Dr. Paul Lammers, CEO of Triumvira Immunologics. "Our abstract presentations at the ASCO (Free ASCO Whitepaper) Gastrointestinal Cancers Symposium underscores our dedication to pioneering advancements in autologous T cell therapy and unveils promising clinical data from our ongoing Phase I/II studies, shedding light on the safety and efficacy of autologous TAC01-HER2 and TAC01-CLDN18.2 in the challenging landscape of solid tumors."

Details of the abstracts for each poster presentation are as follows:

Abstract Number: 747
Title: A phase I/II trial investigating safety and efficacy of autologous TAC01-HER2 in relapsed or refractory solid tumors.
Authors: Benjamin L. Schlechter, Ecaterina Dumbrava, Mridula George, Samuel Saibil, Marcus Butler, Antonio Giordano, Rishi Surana, Chih-Yi Liao, Jordan Weiss, Brooke Pieke, Miriam Gavriliuc, Emily Lichtenstein, Maria Apostolopoulou, Courtney Burke, Bushra Qureshi, Deyaa Adib, & Daniel Olson.
Session: Poster Session A: Cancers of the Esophagus and Stomach and Other GI Cancers
Date: Thursday, January 18 at 11:45 a.m. – 1:15 p.m. Pacific Time
Location: Level 1, West Hall, Poster Board M2

Abstract Number: TPS419
Title: First-in-human phase 1/2 trial evaluating TAC01-CLDN18.2 autologous T cells in CLDN18.2-positive solid tumors.
Authors: Ecaterina Dumbrava, Davendra Sohal, Daniel Olson, Samuel Saibil, Alejandro Urgelles, Maria Apostolopoulou, Amy Mueller, Kara Moss, Deyaa Adib, Benjamin Schlechter, & Syma Iqbal.
Session: Poster Session A: Cancers of the Esophagus and Stomach and Other GI Cancers
Date: Thursday, January 18 at 11:45 a.m. – 1:15 p.m. Pacific Time
Location: Level 1, West Hall, Poster Board N4

On December 19, 2023 Illumina, Inc. (NASDAQ: ILMN) reported that its executives will be speaking at the following investor conference (Press release, Illumina, DEC 19, 2023, View Source [SID1234638692]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024
Presentation at 9:00am Pacific Time (12:00pm Eastern Time) immediately followed by a Q&A Session to begin at approximately 9:20am Pacific Time (12:20pm Eastern Time)

The webcast can be accessed through the Investor Info section of Illumina’s website at investor.illumina.com. A replay will be posted on Illumina’s website after the event and will be available for at least 30 days following.